Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
about
Pharmacology of antihistaminesFruit juice inhibition of uptake transport: a new type of food-drug interactionInternational Union of Basic and Clinical Pharmacology. XCVIII. Histamine ReceptorsWhat is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.Loratadine versus levocetirizine in chronic idiopathic urticaria: A comparative study of efficacy and safety.Pharmacology of antihistamines.Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders.Repurposing Cationic Amphiphilic Antihistamines for Cancer TreatmentAdult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine.Methods to evaluate biliary excretion of drugs in humans: an updated review.A review of the role of levocetirizine as an effective therapy for allergic disease.Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.Drug metabolism and pharmacokinetics.Gender and interindividual variability in pharmacokinetics.Pharmacokinetics in special populations.Levocetirizine in the treatment of allergic diseases.Pharmacokinetic interactions between 20(S)-ginsenoside Rh2 and the HIV protease inhibitor ritonavir in vitro and in vivo.Histamine, histamine receptors and antihistamines: new concepts.Pharmacokinetic evaluation of levocetirizine.An overview of bilastine metabolism during preclinical investigations.H(1)-antihistamines and urticaria: how can we predict the best drug for our patient?Safety evaluation of desloratadine in allergic rhinitis.QTc interval prolongation by fexofenadine in healthy human volunteers and its correlation with plasma levels of fexofenadine: A demonstration of anticlockwise hysteresis.Levocetirizine: a modern H1-antihistamine for the treatment of allergic rhinitis.Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.Prolonged anticholinergic delirium following antihistamine overdose.Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters.Association of FCER1A genetic polymorphisms with risk for chronic spontaneous urticaria and efficacy of nonsedating H1-antihistamines in Chinese patients.Pharmacology of AntihistaminesRapid Dynamic Determination of Cetirizine Dihydrochloride in Urine Using Surface Enhanced Raman Scattering with Silver Colloids
P2860
Q24618798-918BCEDE-FABD-4FF6-BD68-6B0BE51A3E3BQ24630998-0E6AA649-E80E-4EFB-9EC6-9BA66A957ABBQ26827568-87994712-98A9-4C42-97CB-FE61E6BC6992Q33278984-640DFFC5-2491-40D3-BCEA-BB0FF8727A57Q33748891-11C57171-3069-464C-8D67-EE45F78C67E1Q33913076-AAAAA026-2C08-442B-BD0B-6F1E6FDB4674Q34347782-961D4ECA-B839-401D-850D-372DD1220830Q34635320-6E585920-8E57-48D5-8353-199DA545D039Q34988193-ECC90E9F-7B37-48BB-992A-B9E936FB3DC5Q36059021-27B8F089-4BD8-49C7-BB5B-C8DA23A7335DQ36407261-526772D5-573D-427B-A0E9-BB2A69AE665DQ36477423-3D2F62EC-1B21-4837-BD7F-FDC3826514F2Q36495774-A1E1C068-9B27-4558-84B2-3D15BAD0904AQ37111873-9B15D359-8DA1-4D2B-BB26-C7F5D5286049Q37497398-EE5DD90B-4254-4082-A68D-67F8DE8B23CCQ37550548-F55B9C0E-64E7-4A5B-B252-091A2338DDA3Q37550556-61D3E9CE-D463-4A0F-8644-08B830797387Q37550561-34127A2E-DE9C-47AB-AF80-19D75EF75969Q37575658-7E5F12C3-26E3-40C8-B557-3CEEA294D5B8Q37727725-769E8B21-F873-43BB-948D-5B0F60265FB1Q37762461-E5BC1E04-5D30-40B1-8552-0B25554E1B28Q37884622-1847E2B0-196A-47BC-A9E4-A7E395F966A1Q38012183-EA587EE7-013B-45FC-8A8A-82AE31767466Q38044949-4E182DFD-0F9D-4ECF-BA3E-76B13A03674DQ38097964-AFA6300F-D4CE-44F7-AE76-7AF4733F47DCQ41523581-38309342-F98F-4F3F-A70E-F4BF61CA8921Q43061587-77926666-D62C-4271-8716-A2FA4C417DB1Q43067629-FD2855FC-994C-4D94-A7DB-2C100BC9BEE4Q51752646-27B70FD1-2D09-4F7C-A3E0-671ED4F12BCFQ55042422-4D54199A-2A80-401A-9CA6-D4F8ECFAEFD1Q55058713-CDB91D1C-F356-41D9-93E8-486FF879F6B0Q56536196-599F3AE5-3CE1-49A8-910A-3FFD2BEC6984Q58189498-49132C55-DD3D-4247-B185-14A07980265F
P2860
Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@ast
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@en
type
label
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@ast
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@en
prefLabel
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@ast
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@en
P2093
P2860
P1476
Comparison of pharmacokinetics ...... ine and mizolastine in humans.
@en
P2093
M Molimard
M Strolin Benedetti
P2860
P304
P356
10.1111/J.1472-8206.2004.00254.X
P577
2004-08-01T00:00:00Z